Bausch Health (BHC)
(Delayed Data from NYSE)
$8.09 USD
-0.66 (-7.54%)
Updated May 2, 2024 04:00 PM ET
After-Market: $8.10 +0.01 (0.12%) 4:50 PM ET
2-Buy of 5 2
A Value B Growth A Momentum A VGM
Brokerage Reports
Bausch Health Cos Inc. [BHC]
Reports for Purchase
Showing records 61 - 80 ( 147 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
First NOV3 Pivotal Trial Yields Positive Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Ophthalmic Surgical Device Approved; New Supplement Launched; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Amoun Pharmaceutical Co. Sale Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Prospects Brightening; Eye Care Spinout Clarity Near-Term; Raising PT to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Alaway Approval; VYZULTA Reach Widens; XIFAXAN Resolution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Allegro Ophthalmics Purchase Option Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Opthalmics-Focused Spinout Planned; 2Q20 Financials; Lowering PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R